• Saturday, September 23, 2023
  • India
  • Translate to Odia
  • LIVE TV
  • OTV Facebook
  • OTV Twitter
  • OTV Instagram
  • OTV LinkedIn
  • OTV Telegram
  • Koo App
  • OTV Youtube

Topic result for bharat-biotech

 Intranasal Covid Vaccine
DCGI nod to Bharat Biotech's intranasal Covid vaccine for restricted emergency use

This step will further strengthen our collective fight against the pandemic, said Union Health Minister Mansukh Mandaviya.

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech
COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech

The Centre partially funded product development and clinical trials through the Department of Biotechnology's, COVID Suraksha programme.

CEPI partners with Bharat Biotech, others to develop variant-proof Covid vaccine
CEPI partners with Bharat Biotech, others to develop variant-proof Covid vaccine

The CEPI will fund the researchers to conduct activities including immunogen design, preclinical studies, manufacturing process development, and a Phase 1 clinical trial.

Bharat Biotech UpgraBharat Biotech Upgrading Facilitding Facilities As WHO Suspends Covaxin Supplies
Bharat Biotech Upgrading Facilities As WHO Suspends Covaxin Supplies

The WHO said in a statement late on on Saturday that the Covaxin suspension was in response to the outcomes of its post EUL (emergency use authorisation) inspection, held between March 14-22, and the need to conduct process and facility upgrades to address recently identified GMP (good manufacturing practice) deficiencies.

  • Sunday, 03 Apr 2022
  • UN
WHO
WHO Suspends Covaxin Supply To UN Agencies

Bharat Biotech on April 1 announced the temporary slowing down of production of its covid-19 vaccine Covaxin across its manufacturing facilities, having completed its supply obligations to procurement agencies and foreseeing the decrease in demand.

Bharat Biotech's Covaxin
Bharat Biotech Announces Slowing Down Of Covaxin Production

Hyderabad-based vaccine manufacturer Bharat Biotech on Friday announced the temporary slowing down of its Covid vaccine Covaxin's production across its manufacturing facilities.

Nasal Vaccine
Bharat Biotech Gets Nod For COVID-19 Intra-Nasal Vaccine Phase-3 Trials

Bharat Biotech has received approval from the Drug Controller General of India to conduct phase-3 trials for its COVID-19 intra-nasal vaccine (BBV154), sources in the company said on Friday.

Bharat Biotech's Krishna Ella
Couple Behind India's Indigenous Covid Vaccine Gets Padma Bhushan

Dr Krishna Ella and Suchitra Ella, the couple behind Bharat Biotech, which developed India's first indigenous vaccine for Covid-19, have been awarded Padma Bhushan, the third highest civilian award in the country.

BOOSTER WORKING
COVAXIN Booster Dose Data Shows Promising Results

COVAXIN Booster Dose Data Shows Promising Results

Ensure Availability Of Covaxin If Mixed Match Policy For Booster Is Adopted: IMA
No Painkillers Or Paracetamol Recommended After Covaxin Jab: Bharat Biotech

"Through our clinical trials spanning 30,000 individuals, approximately 10-20 per cent individuals report side effects. Most of these are mild, resolve within 1-2 days, and do not require medication. Medication is only recommended only after you consult a physician," the company said.

Phase III Trial Of Bharat Biotech Intranasal Vaccine
DGCI Approves For Phase III Trial Of Bharat Biotech Intranasal Vaccine As Booster

According to a source, Bharat Biotech aims to conduct clinical trials on 5,000 healthy subjects: half or 2,500 individuals who have received Covishield and another 2,500 who have been administered Covaxin.

Covaxin For Children Proven To Be Safe In Paediatric Subjects In Study: Bharat Biotech
Covaxin For Children Proven To Be Safe In Paediatric Subjects In Study: Bharat Biotech

No serious adverse event was reported. 374 subjects reported either mild or moderate severity symptoms with 78.6 per cent getting resolved within one day.

Tesla In-Car Video Games Raise Drivers Safety Concerns
Tesla In-Car Video Games Raise Drivers Safety Concerns

"It is a big concern if it plays in view of the driver, for sure," Jonathan Adkins, executive director of the Governors Highway Safety Association, which coordinates state efforts to promote safe driving, was quoted as saying.

  • Thursday, 09 Dec 2021
  • Tesla
 Covaxin
Covaxin 77.8% Effective Against COVID-19: Lancet study

The phase 3 trial Efficacy and Safety Study involving 25,800 volunteers across 25 sites in India is India's largest ever clinical trial conducted for a Covid-19 vaccine.

Bharat Biotech's US Partner Ocugen Seeks Covaxin Approval For Kids
Bharat Biotech's US Partner Ocugen Seeks Covaxin Approval For Kids

Covaxin uses the same Vero Cell manufacturing platform as other childhood vaccines, including the inactivated polio vaccine.

Finally Approved!
Covaxin Gets WHO Nod; Union Health Minister’s Reaction

Covaxin Gets WHO Nod; Union Health Minister’s Reaction

Covaxin
Australia Recognises India's Covaxin

This recognition is for travellers aged 12 and over who have been vaccinated with Covaxin, and those 18 to 60 who have been vaccinated with BBIBP-CorV.

Covaxin Approved
Finally, Covaxin Approved For Children In 2-18 Yrs Age Group, DCGI Gives Nod

The Drugs and Comptroller General of India (DCGI) has given a go-ahead to Bharat Biotech's Covaxin for vaccination of children in the 2-18 years age group.

Health Min Releases 1st Commercial Batch Of Covaxin From Bharat Biotech's New Plant
Health Min Releases 1st Commercial Batch Of Covaxin From Bharat Biotech's New Plant

India's vaccination coverage against coronavirus under the mass vaccination drive has crossed the landmark of 63 crore. Over 73 lakh doses have been administered in the last 24 hours.

COVID Vaccine
India May Have COVID19 Vaccines For Children By September Or Just After It: ICMR-NIV

The results of Phase II and III trials of COVAXIN are going on for children in the age group of 2-18 years. So, by September or just after it, we may have COVID-19 vaccines for children, said Priya Abraham, Director of ICMR-NIV